Blog
New Approaches for the Value Assessment of Advanced Medical Products
The journal Clinical Drug Investigation recently published the article “New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing” which was co-authored by Dr. Luca Pani, VP Regulatory Strategy and...
VeraSci Partners with Boehringer Ingelheim on Innovative Phase III Program for Breakthrough Therapy in Cognitive Impairment Associated with Schizophrenia
Today, Boehringer Ingelheim announced that they are partnering with VeraSci on an innovative phase III program in cognitive impairment associated with schizophrenia (CIAS) for the investigational treatment BI 425809. The FDA has granted Breakthrough Therapy...
Recent Innovations and their Regulatory Implications for Multiple Sclerosis Trials Addressed in a Special Issue of the Journal of Clinical Neurophysiology by VeraSci Experts
This week, the Journal of Clinical Neurophysiology published a special issue about recent innovations and their regulatory implications for clinical trials in multiple sclerosis. Dr. Mark Skeen, Senior Medical Scientist at VeraSci and Professor of Neurology at Duke...
The Parkinson’s Foundation and the Parkinson’s Study Group Provide Recommendations on Overcoming Challenges in Telehealth for Clinical Research Studies
Members of the Parkinson’s Foundation and the Parkinson’s Study Group (PSG), including VeraSci Senior Clinical Director of Movement Disorders Dr. Travis Turner, recently published a consensus statement titled “Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America” in Nature Partner Journal (NPJ) Parkinson’s Disease. The paper outlines supporting evidence as well as barriers and solutions to implementation.
New Scale for Measuring Non-Motor Fluctuations in Parkinson’s Disease
The Non-Motor Fluctuations Assessment Questionnaire (NoMoFA) is a patient-reported outcome measure that seeks to characterize the non-motor symptoms that may fluctuate in parallel with motor symptoms.
Developing Psychedelics for Use in CNS Disorders
An expanding body of research suggesting that psychedelics could treat CNS disorders like substance abuse, depression, chronic pain, and schizophrenia has sparked a renewed interest in recent years by drug developers and investors.
VeraSci Partners with Aural Analytics to Incorporate Speech Analytics into Pathway eCOA Platform
VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is pleased to announce a new partnership with Aural Analytics, Inc., a global leader in speech analytics for clinical research....
A Transdiagnostic Approach Could Change Drug Development for CNS Disorders
Most products being developed today for CNS diseases and disorders are under development for a specific indication like depression, Parkinson’s disease, or schizophrenia. This approach focuses on obtaining approval to treat patients with a specific diagnosis and...
Examining the Connection Between COVID-19 and Cognition
Increasing evidence is emerging that cognitive symptoms persist well beyond the acute phase of COVID-19 illness and well after patients have cleared the virus.
VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials
Durham, NC—January 19, 2021—VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is pleased to announce a new partnership with ActiGraph, a leading provider of medical-grade wearable...